What OATS surgery actually does to your knee

Articular cartilage — the smooth white tissue lining the ends of the knee's bones — has no blood supply and cannot repair itself once a defect is large enough or deep enough to matter. OATS (Osteochondral Autograft Transfer System) addresses this directly by moving tissue rather than trying to stimulate regrowth.

During the procedure, a surgeon removes one or more small cylindrical plugs of healthy cartilage together with the bone underneath from a low-load zone of the same knee — typically the periphery of the femoral condyle, an area that bears relatively little force during normal activity. Each plug is then press-fitted into the prepared defect site, locking into place without glue or scaffold. Because the transplanted tissue is mature, fully differentiated hyaline cartilage — structurally identical to the native cartilage it replaces — integration begins with the surrounding joint surface rather than with a substitute material.

A single plug is sufficient for defects roughly in the 1–2 cm² range. Where a lesion is somewhat larger, mosaicplasty arranges multiple 6–10 mm plugs side by side, extending coverage to approximately 4 cm².

OATS draws entirely on the patient's own tissue. When a defect is too large for autograft coverage, a separate technique — osteochondral allograft (OCA) — uses donor tissue instead; that distinction matters for candidacy and is discussed below.

Who is a good candidate for OATS

Four practical filters tend to determine whether OATS is the right fit: age, lesion grade, lesion size, and the overall condition of the joint.

Age. A 2024 ROC analysis by Figueroa placed the optimal age cut-off at under 34, though most clinical guidelines extend eligibility to patients under 50. Outcomes are strongest in younger, physically active adults — a pattern consistent across the published literature.

Lesion grade and cause. OATS is indicated for focal, contained defects graded III or IV on the ICRS (International Cartilage Repair Society) scale — meaning the damage reaches partway or fully through the cartilage down to bone. The most common underlying causes are traumatic injury, repetitive overuse, and osteochondritis dissecans (OCD), a condition in which a fragment of bone and cartilage partially or fully detaches. Patients are typically referred for surgery only after conservative management — physiotherapy, activity modification, and injections — has not produced adequate relief.

Joint health. The surrounding cartilage must be healthy and the knee's overall alignment sound. Advanced osteoarthritis, widespread cartilage damage, rheumatoid arthritis, or active infection are contraindications.

Lesion size as a technique guide. Size is often the clearest indicator of which approach fits. Smaller defects suit a single autograft plug; where the defect is larger than autograft can reliably cover, the clinical team may consider OCA or a cell-based option such as ACI or MACI — each a different tool suited to different circumstances, not a lesser outcome.

How OATS compares with microfracture and other repair options

Microfracture produces fibrocartilage; OATS transplants hyaline cartilage. That biological gap drives the difference in long-term durability.

Microfracture punctures the subchondral bone to release marrow cells, which form a fibrin clot that matures into fibrocartilage — a repair tissue that lacks the structural and load-bearing properties of native hyaline cartilage. In published series, functional improvements after microfracture tend to plateau and then decline around the two-to-three-year mark as this tissue degrades under joint load. There is also evidence that the procedure can damage the subchondral bone plate itself, potentially limiting options for any subsequent repair. Microfracture once held a first-line role for smaller defects; current evidence has substantially narrowed that role.

OATS bypasses the problem by delivering mature, fully differentiated cartilage in a single surgical stage — no cell culture step, no second operation.

For larger defects (broadly 2–10 cm²), ACI and MACI are the more appropriate tools. Both produce hyaline-like repair tissue, but each requires two separate procedures — a biopsy to harvest and culture chondrocytes, then a second implantation stage — along with greater resource and recovery investment. They are suited to a different scale of defect, not a superior version of what OATS does.

AMIC (matrix-augmented microfracture) occupies a middle ground: a single-stage procedure that adds a collagen scaffold to standard microfracture to guide cell differentiation, offering a bridge where OATS is not appropriate but two-stage cell therapy would be disproportionate.

What the clinical evidence shows on outcomes

Across published series, clinical success rates for small-to-medium focal lesions sit in the range of 85–93%. That headline figure is a reasonable starting point, but the more informative question is whether early gains last — and here the evidence is unusually consistent.

Short and medium term. Gudas et al. reported good results in 86–90% of patients at three-year follow-up. A retrospective study by Muller (2010) of 15 knees found that 12 of 13 patients returned to sport at an intermediate or high level, with subjective knee scores rising from 4.7 to 7.2 (P=0.007) at a mean follow-up of 42 months — data worth noting for active patients whose primary aim is getting back to sport.

Ten-year persistence. Pareek's 2016 systematic review confirmed that IKDC and Lysholm functional scores remained significantly above pre-operative baseline at ten years. The early gains seen in the short-term data do not appear to be transient: the evidence suggests functional improvements are durable, not a temporary response to surgery.

Twenty-year durability. Keszég (2022) found no significant decline in functional scores at 20 years, and a 2025 case report provided biological corroboration — re-arthroscopy 18 years after surgery confirmed histologically normal cartilage in the transplanted plugs. Functional scores holding at two decades are meaningful; direct tissue evidence that the cartilage remains healthy at 18 years adds weight to those numbers.

Failure and the allograft variant. The overall autograft OATS failure rate is approximately 13% at a mean of 3.6 years — worth acknowledging plainly. For larger defects where autograft supply is insufficient, fresh osteochondral allograft (OCA) is the alternative. In a 2020 study by Bugbee of 91 'ideal' OCA candidates (mean age 20, lesions under 8 cm²), graft survivorship was 99% at both five and ten years, with 93% patient satisfaction. Population-level OCA survivorship is lower — 80% at ten years and 73% at 15 years — reflecting the broader, less-selected patient group.

Most of this evidence comes from retrospective, single-centre studies, which limits direct comparison across populations. That is a transparency note about study design rather than a reason to discount the findings, which are consistent in direction across multiple research groups and time horizons.

Recovery timeline and risks to plan for

Planning recovery around OATS means accounting for one of the longer post-operative timelines in elective knee surgery — and for one risk that is specific to this procedure.

Weeks 0–6. For the first six weeks you will be strictly non-weight-bearing, using crutches to keep load entirely off the operated knee. This is the most physically demanding phase of recovery and should not be shortened — the plugs need time to integrate with the surrounding bone.

Months 3–4. Once integration is confirmed and swelling has settled, low-impact activities such as cycling and swimming become appropriate. Walking distances increase progressively through this period.

Months 6–9 (and up to 12). Return to high-impact sport is typically targeted at six to nine months. High-demand athletes — those returning to running, jumping, or pivoting sports — may require up to twelve months before full clearance.

Donor-site morbidity: the risk specific to OATS

Because OATS uses cartilage harvested from your own knee, the harvest site carries its own risk. Approximately 10–15% of patients experience persistent pain, stiffness, or patellofemoral symptoms at the donor area. Most patients are not affected, but it is a meaningful consideration that distinguishes OATS from techniques that use allograft or cell-based repair.

Standard surgical risks

Deep-vein thrombosis, wound infection, post-operative bleeding, and joint stiffness apply as with any knee procedure and are addressed through standard prophylaxis and monitoring protocols.

Physiotherapy is not an optional add-on — structured rehabilitation at every stage, from early range-of-motion work through to sport-specific conditioning, is an active co-requirement for a good outcome.

Finding the right specialist for OATS

The evidence in this article points toward a fairly clear risk-benefit picture. For patients under 35 with a focal, contained ICRS grade III or IV lesion in an otherwise healthy joint, the 10- and 20-year durability data — supported by direct tissue findings at 18-year re-arthroscopy — make a credible case for the demanding recovery. The calculus becomes harder as lesion size grows, age approaches 50, or the surrounding joint shows wear: at those margins, the choice between OATS, mosaicplasty, OCA, or a cell-based approach requires individual clinical assessment rather than any general answer.

A specialist consultation should cover MRI grading of lesion depth and containment, defect size measurement to determine the most appropriate technique, and a frank discussion of activity goals, donor-site risk, and alternatives. Search MSK lists knee cartilage specialists across the UK — filter by region and treatment offered to find one equipped to carry out that assessment.